The Origins of Tumor-Promoting Inflammation  by Bondar, Tanya & Medzhitov, Ruslan
Cancer Cell
PreviewsChoi, Y.J., Li, X., Hydbring, P., Sanda, T., Stefano,
J., Christie, A.L., Signoretti, S., Look, A.T., Kung,
A.L., von Boehmer, H., and Sicinski, P. (2012).
Cancer Cell 22, 438–451.
Dews, M., Homayouni, A., Yu, D., Murphy, D., Sev-
ignani, C., Wentzel, E., Furth, E.E., Lee, W.M.,
Enders, G.H., Mendell, J.T., and Thomas-Tikho-
nenko, A. (2006). Nat. Genet. 38, 1060–1065.
Fu, M., Wang, C., Li, Z., Sakamaki, T., and Pestell,
R.G. (2004). Endocrinology 145, 5439–5447.Hu, M.G., Deshpande, A., Enos, M., Mao, D.,
Hinds, E.A., Hu, G.F., Chang, R., Guo, Z., Dose,
M.,Mao, C., et al. (2009). Cancer Res. 69, 810–818.
Kollmann, K., Heller, G., Schneckenleithner, C.,
Warsch, W., Scheicher, R., Ott, R.G., Scha¨fer, M.,
Fajmann, S., Schlederer, M., Schiefer, A.I., et al.
(2013). Cancer Cell 24, this issue, 167–181.
Lim, J.T., Mansukhani, M., and Weinstein, I.B.
(2005). Proc. Natl. Acad. Sci. USA 102, 5156–5161.Cancer Cell 24Malumbres, M., Sotillo, R., Santamarı´a, D., Gala´n,
J., Cerezo, A., Ortega, S., Dubus, P., and Barbacid,
M. (2004). Cell 118, 493–504.
Puyol, M., Martı´n, A., Dubus, P., Mulero, F., Piz-
cueta, P., Khan, G., Guerra, C., Santamarı´a, D.,
and Barbacid, M. (2010). Cancer Cell 18, 63–73.
Sawai, C.M., Freund, J., Oh, P., Ndiaye-Lobry, D.,
Bretz, J.C., Strikoudis, A., Genesca, L., Trimarchi,
T., Kelliher, M.A., Clark, M., et al. (2012). Cancer
Cell 22, 452–465.The Origins of Tumor-Promoting InflammationTanya Bondar1 and Ruslan Medzhitov1,*
1HHMI and Department of Immunobiology, Yale University School of Medicine, New Haven, CT 0651, USA
*Correspondence: ruslan.medzhitov@yale.edu
http://dx.doi.org/10.1016/j.ccr.2013.07.016
Inflammation is increasingly recognized as an essential component of tumor development, but the origin
of tumor-associated inflammation remains largely unknown. In this issue of Cancer Cell, Pribluda and
colleagues find that chronic stress initiates senescence-inflammatory response, which can promote tumor-
igenesis in the absence of exogenous inflammatory triggers.Cellular senescence may be compared
to a differentiation program because of
its dramatic effects on cell morphology,
metabolism, and chromatin structure.
Yet, physiological roles of senescence
remain poorly understood.
Because senescence induces perma-
nent cell cycle arrest, it is thought to func-
tion to suppress tumor development
(Rodier and Campisi, 2011). However,
it is unclear why senescence is used
instead of apoptosis, which would perma-
nently eliminate oncogenic cells. The phe-
nomenon of cell senescence is, in many
ways, analogous to T cell anergy, where
autoreactive and potentially harmful
T cells are rendered unresponsive to
stimulation. Why anergic and apparently
unwanted T cells are not eliminated by
apoptosis remains unknown. Likewise
it is unclear why senescent cells are
retained rather than eliminated.
One possible clue to this puzzle is that,
in addition to cell cycle arrest, senescent
cells may have non-cell-autonomous
roles based on their secretory activity.
Indeed, senescence-associated secre-
tory phenotype (SASP) is a common
feature of senescent cells (Rodier and
Campisi, 2011). They primarily releaseproinflammatory cytokines, chemokines,
and extracellular-matrix remodeling fac-
tors. Many of these proteins are critical
in promoting tissue repair and can be
produced in larger quantities by macro-
phages in response to infection or
damage.
The view of senescence as a form of
tissue repair response may explain
another paradox of cell senescence; in
some contexts, it has a tumor-promoting
effect. Tumor growth has features of
deregulated tissue repair, but what
initiates this repair response is unclear.
Tissue repair accompanies the inflamma-
tory response induced by tissue injury.
However, how these responses are
induced in tumors remains poorly under-
stood despite increasing appreciation of
their critical role in tumor development
(Ben-Neriah and Karin, 2011).
The article by Pribluda et al. (2013) in
this issue of Cancer Cell establishes new
functional links between tissue stress,
senescence, low-grade inflammatory
response, and tumor progression. To
introduce these findings, we first need to
address the terminology of senescence
and inflammation, which is often inconsis-
tent and even confusing.By being implicated in diverse biolog-
ical processes, both ‘‘senescence’’ and
‘‘inflammation’’ have been stretched far
beyond their original definitions, often
creating challenges in use and interpreta-
tion. Senescence is often defined by an
arbitrary number of optional markers, pre-
dominantly phenotypic and not always
present together. Every single hallmark
of senescence has been found dispens-
able for at least some of the senescence
states described. Even permanent growth
arrest, the most definitive feature of
senescence, can be missing in some
cases. For example, senescent hemato-
poietic stem cells defined in physiological
aging or genotoxic stress display multiple
senescent markers while retaining partial
proliferative capacity (Chen, 2011).
Because of this vague terminology,
senescence phenotypes reported in
different studies sometimes show little
overlap.
Similarly, ‘‘inflammatory responses’’
differ greatly depending on the nature
of the inducer, responding cells, etc.
Both senescence and inflammation are
induced by stress and share some com-
ponents. Not surprisingly, what is defined
as a senescence response in one setting, August 12, 2013 ª2013 Elsevier Inc. 143
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Previewsmay be more similar to an inflammatory
response in this same setting, rather
than a senescence response in a different
setting.
This terminological paradox and its
elegant resolution are the starting point
of the paper by Pribluda et al. (2013). In
their study, mice with enterocyte-specific
ablation of Csnk1a1 (single knockout
[SKO]) or Csnk1a1 and p53 (double
knockout [DKO]) yield pre-neoplastic or
malignant stages of intestinal carcino-
genesis, respectively. Wnt pathway is
activated in SKO cells but does not result
in tumor development, because it is
counteracted by chronic DNA damage
response and senescence. The senes-
cence appears p53-dependent, because
growth arrest and p21 expression are
ablated in DKO enterocytes, which rapidly
progress to malignancy.
However, senescence markers SA-
b-gal and p19 are still displayed by the
highly proliferative DKO cells. Even more
surprisingly, both SKO andDKO cells pro-
duce elevated levels of numerous inflam-
mation-related factors, which the authors
call senescent-inflammatory response
(SIR). Although the identities of SIR and
SASP genes show little overlap, most
belong to the same functional categories.
Thus, both SIR and SASP may be viewed
as para-inflammation induced by geno-
toxic stress. Accordingly, senescence
can function as two separable stress-
induced responses: (1) tumor suppres-
sive, p53-mediated, cell-autonomous
growth arrest, which is, in essence, a pro-
longed DNA damage checkpoint; and (2)
an inflammatory response (SIR/SASP/
para-inflammation) that promotes tissue
repair by cell-extrinsic mechanisms and
may potentially be tumor promoting.
These results further suggested that
inflammation induced by stress in a cel-
l-autonomous manner may be the elusive
source of tumor-associated inflammation.
Indeed, blocking SIR with non-steroidal
anti-inflammatory drugs (NSAIDs)
decreased tumor burden in DKO mice
and abolished aberrant proliferation and
transformed the phenotype of DKO orga-144 Cancer Cell 24, August 12, 2013 ª2013 Enoid cultures. Because these cultures are
devoid of microbes and immune cells,
these experiments illustrate that cell-
autonomous initiation of inflammation
can play a critical role in oncogenic
transformation.
Which of the many SIR genes are
responsible for this process, and what is
the p53’s role in it? SIR genes are
elevated in SKO and DKO cells, but
induce oncogenic transformation only in
DKO cells. In their previous study,
Pribluda et al. (2013) reported that onco-
genic transformation of DKO cells is
mediated by ‘‘the p53-suppressed inva-
siveness signature’’ (PSIS) genes (Elyada
et al., 2011). These genes are expressed
in DKO but not SKO cells and function in
tissue remodeling, cell adhesion, and
migration. Now, by showing that PSIS
expression is dependent on SIR and
blocked by NSAIDs, the authors seem to
have connected the dots (Pribluda et al.,
2013).
But more questions always follow.
What is the physiological counterpart of
the PSIS program? How does PSIS acti-
vation induce hyperproliferation? One
possible explanation may be provided
by a hypothesis that the proliferation of
stem cells at steady state and during
tissue injury is differentially controlled by
cell interactions.
Stem cells generally depend on con-
tacts with their niche for proliferation, sur-
vival, and self renewal. This dependence
enables the elimination of misplaced
stem cells and controls stem cell
compartment size. Howdo stem cells sur-
vive and massively proliferate upon tissue
injury when the niche is likely to be
damaged? Perhaps in this context,
some injury-induced signals can tempo-
rarily license stem cells to survive and
proliferate outside the niche and migrate
to nearby sites of damage if those ‘‘local’’
stem cells have been destroyed. Niche
disruption would induce tissue remodel-
ing, so the production of the licensing sig-
nals could be coupled to the remodeling
response. This mechanism would ensure
that niche-independent proliferation islsevier Inc.only allowedwhen there is tissue damage.
Once the tissue structure is restored, the
inflammatory response and tissue remod-
eling cease, and proliferation again
becomes restricted by contacts with the
niche.
Consistent with this hypothesis,
NSAIDs only inhibit the proliferation of
DKO cells in ‘‘inappropriate’’ locations,
such as small intestine villi and organoid
culture spheroid bodies. Proliferation
within intestinal crypts and their in vitro
equivalents (organoid ‘‘outpockets’’) was
unaffected by NSAIDs, which is consis-
tent with the idea that signals in the stem
cell niche sustain proliferation by a
distinct mechanism (Pribluda et al., 2013).
Inflammatory factors secreted by se-
nescent cells have been implicated in
cancer progression via several non-cell-
autonomous mechanisms (Ohtani and
Hara, 2013). In contrast, inflammatory
and tissue remodeling factors promoting
tumor progression of DKO enterocytes
are produced and act cell autonomously.
This latter scenario illustrates the principle
that oncogenic transformation can be
induced by low-grade inflammation
resulting from tissue stress (para-inflam-
mation) (Medzhitov, 2008).REFERENCES
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